Home › Funds › General Catalyst Group Management, LLC › MAZE
General Catalyst Group Management, LLC position in MAZE
MAZE THERAPEUTICS INC · Health Care
General Catalyst Group Management, LLC reported holding 1,035,910 shares of MAZE (MAZE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$30.9M, representing 16.40% of its reported portfolio and ranking #4 among its reported holdings. General Catalyst Group Management, LLC has disclosed MAZE holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How General Catalyst Group Management, LLC's MAZE position evolved
General Catalyst Group Management, LLC first disclosed a stake in MAZE in Q1 2025 at 1,035,910 shares (US$11.4M). The position peaked in Q4 2025 at 1,035,910 shares, worth US$42.9M. Across 6 filings, General Catalyst Group Management, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 1,035,910 shares valued at US$30.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2025 | 1.04M | $11.41M | New |
| Q2 2025 | 1.04M | $12.71M | Hold |
| Q3 2025 | 1.04M | $26.86M | Hold |
| Q4 2025 | 1.04M | $42.92M | Hold |
| Q1 2026 | 1.04M | $30.92M | Hold |
| Q2 2026 | 1.04M | $30.91M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MAZE and 13F data
MAZE (MAZE THERAPEUTICS INC) is a Health Care company. 74 other funds we track also report a position in MAZE — the largest reported positions include Frazier Life Sciences Management, L.P. (US$150.2M), TRV GP IV, LLC (US$133.5M), ARCH Venture Management, LLC (US$123.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MAZE
- Frazier Life Sciences Management, L.P. 5.03M sh · $150.18M · Q2 2026
- TRV GP IV, LLC 4.47M sh · $133.50M · Q2 2026
- ARCH Venture Management, LLC 4.12M sh · $122.98M · Q2 2026
- Deep Track Capital, LP 3.73M sh · $111.38M · Q2 2026
- Logos Global Management LP 1.94M sh · $57.74M · Q2 2026
- a16z Capital Management, L.L.C. 1.70M sh · $50.79M · Q2 2026
- Venrock Adviser, LLC 1.60M sh · $47.80M · Q2 2026
- Alphabet Inc. 1.39M sh · $41.44M · Q2 2026
- BRAIDWELL LP 1.14M sh · $34.02M · Q2 2026
- Farallon Capital Management 1.11M sh · $33.06M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 1.11M sh · $33.06M · Q2 2026
- TRV GP V, LLC 950.80K sh · $28.37M · Q2 2026
More on General Catalyst Group Management, LLC
FAQ
How long has General Catalyst Group Management, LLC held MAZE?
General Catalyst Group Management, LLC has disclosed MAZE holdings in 6 of the last 6 reported quarters, going back to Q1 2025.
What is General Catalyst Group Management, LLC's current position in MAZE?
As of Q2 2026, General Catalyst Group Management, LLC holds 1.04M shares of MAZE (MAZE THERAPEUTICS INC), valued at $30.91M, representing 16.40% of its reported portfolio and ranking #4.
Has General Catalyst Group Management, LLC been buying or selling MAZE?
In the latest 13F filing (Q2 2026), General Catalyst Group Management, LLC held unchanged its position in MAZE. The position peaked in Q4 2025 at 1.04M shares.
Which other funds hold MAZE?
Other major institutional holders of MAZE include Frazier Life Sciences Management, L.P., TRV GP IV, LLC, ARCH Venture Management, LLC, among 74 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.